Related Topics News -

     
 Title only   |   Print 
     
《大行》匯豐研究:醫療健康行業受穩健需求支持 看好信達生物、科倫博泰、藥明康德

2026-09-09T  
和鉑醫藥及科倫博泰:HBM9378/WIN378治療哮喘啟動III期研究

2026-09-09T  
《大行》里昂:中國生物科技基本面仍穩固 首選百濟神州、信達生物及維立志博

2026-09-04T  
國家醫保局:更多創新藥有望納入醫保報銷 續推動靈活就業人員等參加職工醫保

2026-09-04T  
《信而有證》港股下試兩萬五水平 黃金股再度受壓 部分生科股逆市升 騰訊、阿里好倉積極

2026-09-02T  
《信而有證》生物醫藥股早段普遍造好 捕捉生科板塊機遇 留意全新上市華夏恆生生科認購證16698/16696

2026-08-26T  
《大行》花旗升科倫博泰生物目標價至625元 移除「高風險」評級

2026-08-20T  
《大行》美銀證券升科倫博泰目標價至644.4元 料全年扭虧

2026-08-19T  
《大行》里昂升科倫博泰目標價至626.4元 上半年淨利潤勝預期

2026-08-19T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.